Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
16.05
+0.07 (0.44%)
At close: Oct 31, 2025, 4:00 PM EDT
16.39
+0.34 (2.12%)
After-hours: Oct 31, 2025, 7:58 PM EDT
Immunome Revenue
Immunome had revenue of $4.01M in the quarter ending June 30, 2025, with 69.84% growth. This brings the company's revenue in the last twelve months to $12.59M, up 16.74% year-over-year. In the year 2024, Immunome had annual revenue of $9.04M, down -35.50%.
Revenue (ttm)
$12.59M
Revenue Growth
+16.74%
P/S Ratio
92.40
Revenue / Employee
$106,686
Employees
118
Market Cap
1.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.04M | -4.98M | -35.50% |
| Dec 31, 2023 | 14.02M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
IMNM News
- 2 days ago - Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference - Business Wire
- 10 days ago - Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance - Business Wire
- 4 weeks ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Infinimmune Announces Research Collaboration with Immunome - Business Wire
- 2 months ago - Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Business Wire
- 2 months ago - Immunome: SpringWorks Buyout Informs The Potential Upside Here - Seeking Alpha
- 3 months ago - Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 5 months ago - Immunome to Present at Upcoming Investor Conferences - Business Wire